Add to ORKGRosiglitazone was noninferior to metformin plus sulfonylurea for CV events but increased risk for HF and fractures in type 2 diabetes Home PD, Pocock SJ, Beck-Nielsen H, et al. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial
We evaluated the effect of glimepiride plus metformin and rosiglitazone plus metformin on glucose, a...
AIMS: To compare glucose control over 18 months between rosiglitazone oral combination therapy and c...
BACKGROUND: A recent meta-analysis raised concern regarding an increased risk of myocardial infarcti...
BACKGROUND: Rosiglitazone is an insulin sensitiser used in combination with metformin, a sulfonylure...
Summary Background Rosiglitazone is an insulin sensitiser used in combination with metformin, a sulf...
AIMS/HYPOTHESIS: Studies suggest that in addition to blood glucose concentrations, thiazolidinedione...
Aims Thiazolidinediones are insulin sensitizers, and are associated with fluid retention and increas...
Type 2 diabetes is a common disease associated with an increased risk of long-term complications, in...
Type 2 diabetes is a common disorder with an increased risk of macrovascular complications. Achievin...
Type 2 diabetes is a common disorder with an increased risk of macrovascular complications. Achievin...
The best treatment option for patients with type 2 diabetes in whom treatment with metformin alone f...
Diabetes is a well-known risk factor of cardiovascular morbidity and mortality, and the beneficial e...
Background and aims: Metformin is the first-line therapy in type 2 diabetes. In patients inadequate...
AIMS: Thiazolidinediones are insulin sensitizers, and are associated with fluid retention and increa...
Metformin is the first-line therapy in type 2 diabetes. In patients inadequately controlled with met...
We evaluated the effect of glimepiride plus metformin and rosiglitazone plus metformin on glucose, a...
AIMS: To compare glucose control over 18 months between rosiglitazone oral combination therapy and c...
BACKGROUND: A recent meta-analysis raised concern regarding an increased risk of myocardial infarcti...
BACKGROUND: Rosiglitazone is an insulin sensitiser used in combination with metformin, a sulfonylure...
Summary Background Rosiglitazone is an insulin sensitiser used in combination with metformin, a sulf...
AIMS/HYPOTHESIS: Studies suggest that in addition to blood glucose concentrations, thiazolidinedione...
Aims Thiazolidinediones are insulin sensitizers, and are associated with fluid retention and increas...
Type 2 diabetes is a common disease associated with an increased risk of long-term complications, in...
Type 2 diabetes is a common disorder with an increased risk of macrovascular complications. Achievin...
Type 2 diabetes is a common disorder with an increased risk of macrovascular complications. Achievin...
The best treatment option for patients with type 2 diabetes in whom treatment with metformin alone f...
Diabetes is a well-known risk factor of cardiovascular morbidity and mortality, and the beneficial e...
Background and aims: Metformin is the first-line therapy in type 2 diabetes. In patients inadequate...
AIMS: Thiazolidinediones are insulin sensitizers, and are associated with fluid retention and increa...
Metformin is the first-line therapy in type 2 diabetes. In patients inadequately controlled with met...
We evaluated the effect of glimepiride plus metformin and rosiglitazone plus metformin on glucose, a...
AIMS: To compare glucose control over 18 months between rosiglitazone oral combination therapy and c...
BACKGROUND: A recent meta-analysis raised concern regarding an increased risk of myocardial infarcti...